Bi-specific T-cell engagers as a bridge to ciltacabtagene autoleucel in Relapsed/Refractory multiple myeloma: Real-world outcomes in an underserved urban population
Retrospective review highlights safety and response rate of bispecific T-cell engagers in multiple myeloma, suggesting improved outcomes in diverse populations.
Key Points
Ciltacabtagene autoleucel achieved an overall response rate of 91.9% in patients with relapsed/refractory multiple myeloma.
Among patients receiving bi-specific T-cell engagers, 59% experienced adverse events compared to 81% without bridging, indicating favorable safety.
Retrospective chart review assessed outcomes of 49 patients treated with CAR-T therapy and BiTE bridging for multiple myeloma from 2023 to 2025.
Findings support the need for increased access to effective therapies within racially diverse populations significantly affected by clinical research disparities.